Please enable JS

Blue Companion

BLUE COMPANION provides digital services for health through private-public partnership projects. They also offer CRO services by designing and conducting clinical studies, as well as providing project management and study management services. Their privileged therapeutic domains are neurodegenerative and neuromuscular diseases, as well as ophthalmology.

 

BLUECompanion also designs, deploys and manages customised integrated ICT platforms to treat and monitor on quasi real time different data sources (auto-evaluation questionnaires, wearable devices, robotic interfaces, mobile phones…).

 

Learn more: www.bluecompanion.eu

A LEADING POSITION AND
AN INTERNATIONAL DEPLOYMENT

64 +

countries
involved

20 000 +

investigational
Centres

3 million +

patients
in database

50 000 +

users
worlwide

telemedicine technologies earth

LATEST NEWSOUR NEWS >

telemedecine technologies news

xShare Webinar – Buying innovation: the format (EEHRxF)

June 26, 2025

June 30 – 4:00 PM to 5:15 PM (CET) xShare, an EU-funded project, strengthens procurement capabilities in digital health by translating the European Electronic Health Record Exchange Format (EEHRxF) into concrete requirements for tenders. This inaugural webinar presents key EU rules and promotes the procurement of interoperable solutions. It aims to raise awareness, share innovative […]

READ MORE
telemedecine technologies news

Japan Health Exhibition 2025

June 26, 2025

June 25–27 – JETRO – Japan External Trade Organization Pavilion – Osaka Booth Hall 6‑A, A‑0408 Philippe Haran – MD, is representing Telemedicine Technologies at the Japan Health Exhibition 2025, as a guest of Micron, Inc., a valued member of our CROAlliance partner. At Micron’s booth, he’s engaging with healthcare leaders and exploring collaboration opportunities […]

READ MORE
telemedecine technologies news

Future proofing your outsourcing strategy: how to stay agile in a fast-moving clinical trial ecosystem

June 26, 2025

Applied Clinical Trials Online At a time when artificial intelligence (AI) is redefining industries at an unprecedented pace, the pharmaceutical sector stands on the brink of a progressive transformation. AI is not just a tool but a catalyst that promises to accelerate drug development timelines in ways we’ve never seen before. However, the true potential […]

READ MORE